Cronos CRON stock analysis and how Cronos CRON stock gets to profitability

Lex­eo Ther­a­peu­tics will be­gin trad­ing on the Nas­daq on Fri­day morn­ing via a $100 mil­lion ini­tial pub­lic of­fer­ing. The car­diac and Alzheimer’s gene ther­a­py biotech

Au­rinia Phar­ma­ceu­ti­cals said it was un­able to at­tract any for­mal of­fers dur­ing its strate­gic re­view process, which be­gan last sum­mer af­ter calls from share­hold­ers MKT